Tofacitinib is a topical small-molecular JAK inhibitor that decreases the JAK-STAT signal in keratinocytes and inhibits IL-4.85,86 Its effectiveness has been shown in plaque psoriasis and AD.87, -89 In AD, the mean EASI score was significantly improved in patients receiving tofacitinib (−81.7%) compared to those treated with vehicle (−29.9%) at week 4.89 Its oral form has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and polyarticular course juvenile idiopathic arthritis.90 Here, IL4 is linked to Alzheimer disease.